NanoPass collaborates with Pharma companies on solutions for COVID-19

In the interests of developing an effective and affordable vaccine, NanoPass is collaborating with global immunotherapy and vaccine companies by sharing its MicronJet microneedle device that targets immune cells of the skin by harnessing the skin’s potent immune system to improve vaccines and/or significantly lower the dose while maintaining the same immunity.

NanoPass says its technology is backed up by more than 55 clinical studies with various vaccines and vaccine platforms, including H1N1, H5N1 and seasonal flu, live attenuated VZV vaccine, that have shown improved immunogenicity and significant dose-sparing. Pre-clinical evidence with mRNA and DNA vaccines showed promising results. The company says it has previously supported US CDC in a Phase 3 infant polio vaccination trial; with ITRC on PPD skin testing; in Type 1 Diabetes immunotherapy; and supported NIAID with devices to evaluate immunogenicity of a pandemic flu vaccine; and multiple vaccine pharma.

CEO of NanoPass, Yotam Levin, said: “The human skin is our first layer of defense against many infectious diseases. The skin contains specialized Dendritic Cells that process and induce strong immune responses – that’s why microneedle injections enable reduction of vaccine doses by 5 fold, thereby reducing overall cost, required capacity and production time. We believe a reliable injection into the skin is critical for successful activation of broad and effective immune responses, which should be explored for most injectable vaccines.”